Syngene International Limited

Introducing our first session in the DMPK Unravelled webinar series! Join us for an in-depth look at ADME strategy and challenges tailored for heterobifunctional degraders.   📅 Date: December 4, 2024 🕙 Time: 10:00 am EST / 7:30 pm IST   This session will explore the complexities of Targeted Protein Degradation (TPD) and overcoming ADME challenges associated with large degrader molecules. Our keynote speaker for the first webinar, Prasoon Chaturvedi, Vice President, Head of DMPK at C4 Therapeutics, Inc., will discuss the application of strategic DMPK screening to support the development of effective and orally bioavailable protein degraders, while our in-house speakers - Vishwottam Kandikere and Amol Raje, will discuss some case studies on the same.   Register now!   #Webinar #DMPK #DMPKUnravelled #Syngene #DrugDiscovery

High titers and shorter timelines are essential for efficient protein production. Enhancing gene expression consistency during the cell line development stage is a crucial strategy to overcome this challenge.   Check out our latest feature on BioPharma Dive, where we explore the key bottlenecks in gene expression and share effective solutions to streamline processes and improve reliability.   Read the full article 👉 https://lnkd.in/gxuY9dEf   #Biologics #ProteinProduction #GeneExpression #CellLineDevelopment #Syngene #Biopharma #ResearchInnovation #SynWeave

In our latest viewpoint, we discuss how to establish the connection between clinical and bioanalytical teams to ensure successful outcomes of GLP/GCLP large molecule bioanalytical sample analysis. Read now! https://lnkd.in/gpz4X5rX #Syngene #Drugdevelopment #Bioanalytical

Syngene celebrated the 5th edition of PRAKALP to mark International Project Management Day, bringing together professionals to share insights and celebrate excellence in project management.   We were honored to host Dr. Tessy Thomas, a distinguished Indian scientist and former Director General of Aeronautical Systems at DRDO, as the chief guest. Renowned as the "Missile Woman of India," she shared invaluable lessons on managing complex projects, drawing from her experience with India's long-range missile program, Agni.   Her insights underscored the power of teamwork, precision, emotional intelligence and perseverance in navigating intricate challenges—a truly inspiring session for all attendees!   Here’s to fostering innovation and leadership in project management. #Syngene #PRAKALP #ProjectManagement #Leadership #Innovation

Know the experts behind the first webinar in the DMPK Unravelled series! With decades of experience in ADME and drug discovery, our speakers bring valuable insights into heterobifunctional degrades. Don’t miss this opportunity to learn from the leaders in the field Prasoon Chaturvedi Vishwottam Kandikere Amol Raje! 📅 Date: December 4, 2024 🕙 Time: 10:00 am EST / 7:30 pm IST / 11:00 pm JST Register now: https://lnkd.in/gWtb847X #Webinar #DMPK #ProteinDegraders #SyngeneDiscovery

Syngene successfully concluded the second edition of its Annual Supplier Summit and Awards, bringing together over 100 suppliers from the CRDMO sector. The event, centered around the theme "Local Sourcing, Global Standards: India at an Opportune Moment to Build the Future of CRDMO," focused on India’s immense potential to lead in innovation, sustainability, and excellence in the CRDMO industry.   We were honored to have Darshan H.V., Director of Electronics, Information Technology, Biotechnology, and Science & Technology for the Government of Karnataka and Managing Director of KITS, as the chief guest. Mr. Shakthi M. Nagappan, Director of Life Sciences and Pharma for the Telangana Government and CEO of Telangana Life Sciences, contributed as a panelist during the event.   This year’s summit reinforced our collective commitment to shaping India’s future as a global leader in the CRDMO industry. A heartfelt thanks to all our partners and participants for their contributions to making this summit a success.   #SupplierSummit2024 #Innovation #Sustainability #Pharma #IndiaAtTheForefront #Karnataka #Telangana

📌We are excited to attend the ACT 2024 Annual Meeting at Austin, Texas from November 17 to 20, 2024. Meet our experts to discuss how Syngene can help you accelerate your drug discovery programs. To book a meeting, visit the link in the comments section. We offer a full range of exploratory and good laboratory practice (GLP) toxicology services that enable clients to assess the safety profile of new drugs (NMEs), agrochemicals, vaccines, cosmetics, and food additives. Our capabilities include - ⦿ Full range of toxicology services including in silico, in vitro, genotox, rodent, and non-rodent studies. Over 750 in-vitro and 500+ in-vivo tox studies have been completed in the last five years and submitted to global regulatory agencies successfully. ⦿ 13+ comprehensive IND-enabling tox packages delivered in the last 5 years for US, European and Japanese clients. ⦿ Experience with biocompatibility testing (ISO 10993) testing of medical devices in ISO/IEC-17025 (NABL, India) and GLP-accredited facilities. ⦿ Analytical and Bioanalytical support under GLP environment. ⦿ OECD and ICH guidelines-compliant clinical pathology and histopathology services ⦿ In-house SEND capabilities are fully compliant with US-FDA requirements. ⦿ Team of 65+ people, including 9 DABTs, 3 ERTs, and four board-certified veterinary pathologists, to support your projects within the best turnaround timelines. #SyngeneDiscovery #ACTmeeting2024 #Toxicology #SafetyAssesment

We’re excited to attend Biofit 2024 in Lille, France, from December 3rd to 4th, 2024. Visit us at booth #B-36 to meet our experts and discover how Syngene can support your journey from discovery through development to market. With over 6,000 scientists and industry experts, Syngene has the expertise and capacity to deliver excellent science, robust data management, IP security, and high-quality manufacturing. We partner with early-stage companies, start-ups, and Big Pharma to accelerate time-to-market and reduce the cost of innovation across the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. To book a meeting, visit the link in the comments section. #DrugDiscovery#CRDMO #Biofit2024

📌 #Blog Discover how Syngene developed a robust LC-MS-based quantitative method to measure the biomarker 2-AG in mice brain tissues, advancing research for mood and anxiety disorder treatments. Read now 👇 https://lnkd.in/gdBqPMUS #SyngeneDiscovery #DMPK #Biomarker

Bile-iant Innovation: Cholestatic Disease Treatment A prominent biotech company collaborated with Syngene to develop a first-in-class inhibitor targeting cholestatic diseases. Through cutting-edge medicinal chemistry and rigorous profiling, our team identified a potent molecule that reduces bile acid concentration, marking significant progress in treating this condition. The novel drug is now advancing to preclinical development, showcasing the power of strategic partnerships in accelerating drug discovery and development. Read the full case study 👉 https://lnkd.in/gdVHsC5i #NASH #Noveldrug #DMPK #ADME